Loading...
Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
S-1, an oral pyrimidine fluoride-derived agent, is effective against various cancers. Sorafenib, an oral multikinase inhibitor, was found to prolong the survival of various cancers and enhance the cytotoxicity of chemotherapeutic agents. We conducted a phase I dose escalation study to determine dose...
Saved in:
| Published in: | Sci Rep |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Nature Publishing Group UK
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7921110/ https://ncbi.nlm.nih.gov/pubmed/33649501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-84279-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|